Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

OTHER 1696INDUSTRY 305NIH 206NETWORK 64OTHER_GOV 23UNKNOWN 10INDIV 1FED 1

Study Type

Interventional 1

Sponsor

Cancer Type

CNS 1

Conditions

Prostatic Neoplasms 53Colorectal Neoplasms 42Neoplasms 37Lung Neoplasms 22Breast Neoplasms 15Colonic Neoplasms 14Colonic Polyps 13Rare Diseases 9Carcinoma, Non-Small-Cell Lung 9Carcinoma, Hepatocellular 9Ovarian Neoplasms 7Adenoma 7Pulmonary Disease, Chronic Obstructive 6Neoplasm Metastasis 6Heart Failure 6Rectal Neoplasms 5Motor Activity 5Liver Neoplasms 5Head and Neck Neoplasms 5Fibrosis 5Carcinoma, Squamous Cell 5Barrett Esophagus 5Uterine Cervical Neoplasms 4Urinary Bladder Neoplasms 4Neoplasms by Site 4Mental Disorders 4Lymphoma 4Lung Diseases 4Leukemia 4Esophageal Neoplasms 4

Interventions

Streptozocin 1Mercaptopurine 1Carmustine 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
FED × Brain Neoplasms × Clear all
NCT00004688 2015-03-25

Phase II Study of Carmustine, Streptozocin, and Mercaptopurine for Refractory or Recurrent Brain Neoplasms

FDA Office of Orphan Products Development

Phase 2 Completed
35 enrolled
CNS

Astrocytoma, Brain Neoplasms, Glioblastoma, Glioma, Oligodendroglioma, Genetic Diseases, Inborn, Rare Diseases

Data powered by HemOnc (CC BY 4.0) Colophon âš¡